Bradley Hunter, MD. MPH

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Kite Pharma
    Topic: 
    CAR T-cell therapy
    Date added: 
    06/24/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    BMS
    Topic: 
    CAR T-cell therapy
    Date added: 
    06/24/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Janssen
    Topic: 
    Bispecifics
    Date added: 
    06/24/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    ADC Therapeutics
    Topic: 
    Lymphoma therapies
    Date added: 
    06/24/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Notable Labs
    Topic: 
    Clinical Trial design
    Date added: 
    06/24/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Novartis
    Topic: 
    CAR T-cell therapy
    Date added: 
    06/24/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Genmab
    Topic: 
    Bispecifics
    Date added: 
    06/24/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    AbbVie
    Topic: 
    Lymphoma therapies
    Date added: 
    06/24/2022
Return to 2022 Cellular Therapy Conference – Translating recent evidence on cellular therapy to real world management of malignancies